chemical:semaglutide
Another GLP1 Generic launch: India's Dr Reddy's
Yet another manufacturer signs up to produce generic Semaglutide for much of the world (ex. EU and USA) - what does Dr. Reddy's have planned?
GLP1.Guide Staff
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
company:hims
Hims will sell generic Semaglutide in 2026
Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
company:novo-nordisk
Novo Nordisk is introducing a higher dose of Wegovy
Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
company:weight-watchers
Novo's expanding collaboration with Weight Watchers
Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
drug:wegovy
Less for Less: CVS drops Zepbound for Wegovy
CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).
includes:study
If GLP1 is so great, why don't people stick with it?
Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.
category:news
A glowing endorsement of GLP1s by cardiologists
Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
category:risks
A new risk? Macular Degeneration
We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.
drug:orforglipron
Updates from MariTide & Orforglipron research
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
chemical:semaglutide
After two months, Novo Nordisk and HIMS part ways
Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
category:news
Preserving muscle: GLP1s with Bimagrumab
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
company:novo-nordisk
Novo Nordisk patent protections lapse in Canada
Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.